Age-adjusted comorbidity score stratifies mortality in prostate CA

June 25, 2015
Age-adjusted comorbidity score stratifies mortality in prostate CA

(HealthDay)—An age-adjusted prostate cancer-specific comorbidity index (PCCI) can stratify the risk of long-term nonprostate cancer-related mortality, according to a study published in the July issue of The Journal of Urology.

Timothy J. Daskivich, M.D., from the David Geffen School of Medicine at the University of California-Los Angeles, and colleagues sampled 1,598 men diagnosed with between 1998 and 2004. The authors determined the risk of nonprostate cancer-related mortality associated with age at diagnosis and PCCI score in testing and validation cohorts. Risk was converted into a 10-point scoring system.

The researchers found that in the testing and validation cohorts, PCCI score and age correlated with similar hazards of other-cause mortality. Equivalent risks were seen for each six-year increase in age at diagnosis of greater than 60 years and for one additional PCCI point. The age-adjusted PCCI scores were strongly predictive of other-cause mortality. For a score of 0, 1 to 2, 3 to 4, 5 to 6, 7 to 9, and 10+, the subhazard ratios of other-cause mortality versus 0 were 2.0, 4.0, 8.7, 14.7, and 43.2, respectively; 10-year cumulative incidence of other-cause mortality was 10, 19, 35, 60, 79, and 99 percent, respectively.

"The -adjusted PCCI strongly stratifies the risk of long-term, other-cause ," the authors write. "It may be incorporated into shared decision-making to decrease overtreatment of older and chronically ill men with cancer."

One author disclosed a financial tie to WiserCare.

Explore further: Benefit of aggressive prostate CA Tx weakens as comorbidity rises

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Benefit of aggressive prostate CA Tx weakens as comorbidity rises

May 21, 2014
(HealthDay)—For men with early-stage prostate cancer, the cancer-specific survival benefit associated with aggressive prostate cancer treatment is reduced with increasing comorbidity, according to a study published online ...

Aspirin use not found to benefit prostate cancer mortality

April 14, 2015
(HealthDay)—Aspirin use does not appear to reduce the risk of mortality associated with prostate cancer, according to research published in the April issue of The Journal of Urology.

Age, creatinine, ejection fraction predict post-MI survival

April 20, 2015
(HealthDay)—A simple age, creatinine, and ejection fraction (ACEF) score can predict one-year mortality risk in myocardial infarction 30-day survivors who underwent percutaneous coronary intervention, according to a study ...

Prostate cancer mortality benefit seen for family Hx-based screens

January 19, 2015
(HealthDay)—Screening white men with a family history of prostate cancer appears to be associated with a decrease in prostate cancer-specific mortality, according to a study published in the January issue of The Journal ...

Risk score IDs one-year mortality in elderly with NSTE-ACS

June 19, 2015
(HealthDay)—A risk score involving five covariates can predict one-year mortality risk in patients ≥75 years presenting with non-ST-segment elevation (NSTE) acute coronary syndromes (ACS), according to a study published ...

Age-related macular degeneration, mortality linked

May 12, 2015
(HealthDay)—Age-related macular degeneration (AMD) is a predictor of poor survival, especially among women aged 80 years and older, according to a study published online May 4 in the Journal of the American Geriatrics Society.

Recommended for you

Researchers discover specific tumor environment that triggers cells to metastasize

November 21, 2017
A team of bioengineers and bioinformaticians at the University of California San Diego have discovered how the environment surrounding a tumor can trigger metastatic behavior in cancer cells. Specifically, when tumor cells ...

New study points the way to therapy for rare cancer that targets the young

November 21, 2017
After years of rigorous research, a team of scientists has identified the genetic engine that drives a rare form of liver cancer. The findings offer prime targets for drugs to treat the usually lethal disease, fibrolamellar ...

Clinical trial suggests new cell therapy for relapsed leukemia patients

November 20, 2017
A significant proportion of children and young adults with treatment-resistant B-cell leukemia who participated in a small study achieved remission with the help of a new form of gene therapy, according to researchers at ...

Cell-weighing method could help doctors choose cancer drugs

November 20, 2017
Doctors have many drugs available to treat multiple myeloma, a type of blood cancer. However, there is no way to predict, by genetic markers or other means, how a patient will respond to a particular drug. This can lead to ...

Researchers discover a new target for 'triple-negative' breast cancer

November 20, 2017
So-called "triple-negative" breast cancer is a particularly aggressive and difficult-to-treat form. It accounts for only about 10 percent of breast cancer cases, but is responsible for about 25 percent of breast cancer fatalities.

Study reveals new mechanism used by cancer cells to disarm attacking immune cells

November 20, 2017
A new study by researchers at The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute (OSUCCC - James) identifies a substance released by pancreatic cancer cells that protects ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.